skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration
Make the most of Bio Europe 2017 with essential partnering information from Informa Pharma Intelligence. Our insightful whitepaper, Partnering in the Pharma World, contains critical information on the landscape for biotech partnerships, and is now available for you to download – free.

Partnering in the Pharma World: BIO-Europe® and Industry Trends 2017 Update

  • H2 2016 and 1Q 2017 continued the brisk pace of biopharma partnering; however, Q2 2017 showed a decline with a total disclosed partnership deal value of only $9.5bn.
  • Oncology deals once again dominated in both number of deals and total deal value.
  • Partnerships signed with assets at either preclinical or marketed phases accumulated most of the deal volume.
  • Attractive partnering options with public companies were identified, especially those with limited cash. Newcomers include companies with partnered cell therapies and orphan drugs.
Partnering in the Pharma World

Read also

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • Biomedtracker: follow the drug development process

    Report Extract: Q3 2017 Outlook Report

    17 Jul 2017

    In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

    Topics Alzheimers Cancer Drug approval

  • Scrip: industry news and insights

    Bayer Bets On Oncology Pipeline Vows To Increase 2017 R&D Budget

    By Lucie Ellis 22 Feb 2017

    Bayer has launched an internal oncology R&D unit to speed up development of its pipeline cancer therapies and ensure the company is first to market with its late-stage treatment candidates, head of pharma Dieter Weinand told Scrip on the sidelines of the pharma's annual results conference.

    Topics Cancer $name

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907
  • Japan            : +81 3-6273-4257

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: